IL1B and myocardial infarction: Starting with the JUPITER (Justification for the Use of Statin in Prevention: An Intervention Trial Evaluating Rosuvastatin) trial, which showed that—in addition to low-density lipoprotein cholesterol (LDL-C) levels—hsCRP levels can also be a marker for predicting the reduction of cardiovascular event risk with statin therapy [2], the CANTOS (Canakinumab Antiinflammatory Thrombosis Outcome Study) showed that canakinumab, a human anti-IL-1β monoclonal antibody, is effective in the secondary prevention of myocardial infarction (MI) [3].